NCT02876679 (ATG-CyGVHD) is a Phase 2 clinical trial of Cyclophosphamide in Graft vs Host Disease, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT02876679?

NCT02876679 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT02876679?

Interventions in NCT02876679: Cyclophosphamide, Anti-Thymocyte Globulin, Conditioning regimen.

What condition does NCT02876679 study?

NCT02876679 studies Graft vs Host Disease.

Is NCT02876679 still recruiting?

NCT02876679 is currently completed. Last updated 20 November 2020.

Last reviewed 2020-11-20 · How we verify

NCT02876679: ATG-CyGVHD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT

Completed Phase 2 Last updated 20 November 2020

What this trial tests

Phase 2 trial testing Cyclophosphamide in Graft vs Host Disease in 94 participants. Completed in 12 October 2020.

Timeline

6 April 2017

Primary endpoint
12 October 2020

12 October 2020

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	94
Start date	6 April 2017
Primary completion	12 October 2020
Estimated completion	12 October 2020
Sites	1 location across France

Drugs / interventions tested

Cyclophosphamide (cyclophosphamide) — full drug profile →
Anti-Thymocyte Globulin
Conditioning regimen — full drug profile →

Conditions studied

Graft vs Host Disease — all drugs for Graft vs Host Disease →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 18 to 65, any sex, with Graft vs Host Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is designed as a two arm randomized Phase II, multicenter trial comparing cyclophosphamide to anti-thymocyte globulin for Graft-versus-Host Disease (GVHD) prophylaxis in patients with hematologic malignancies undergoing reduced intensity conditioning hematopoietic stem cell transplantation.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation.
Williams L, Cirrone F, Cole K, Abdul-Hay M, et al · · 2020 · cited 32× · PMID 32373119 · DOI 10.3389/fimmu.2020.00636
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Brissot E, Labopin M, Labussière H, Fossard G, et al · · 2024 · cited 18× · PMID 38374026 · DOI 10.1038/s41408-024-00990-3
How to improve the outcomes of elderly acute myeloid leukemia patients through allogeneic hematopoietic stem cell transplantation.
Jiang S, Yan H, Lu X, Wei R, et al · · 2023 · cited 1× · PMID 37207218 · DOI 10.3389/fimmu.2023.1102966
47th Annual Meeting of the EBMT.
Del Pozo Martín Y. · · 2021 · cited 1× · PMID 33811823 · DOI 10.1016/s2352-3026(21)00104-6

Verify or expand the search:

Other trials of Cyclophosphamide

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07509008 — Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Manageme · Phase 1, PHASE2 · not yet recruiting
NCT07444632 — Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/ · Phase 1 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Graft vs Host Disease

Currently open trials in the same condition.

NCT07184853 — Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD · NA · recruiting
NCT06568328 — Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD · Phase 1 · recruiting
NCT05531786 — Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) Af · Phase 1, PHASE2 · recruiting
NCT04044365 — Pediatric cGVHD Symptom Scale · recruiting
NCT02105766 — Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Bet · Phase 2 · active not recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02876679 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 20 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02876679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing